Clinical Trials

500 enrolled

Non Squamous Non-small Cell Lung Cancer

NCT07360132 2026-01-22

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

480 enrolled

Phase 2/3 Not yet recruiting

Squamous Non-small Cell Lung Cancer

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

720 enrolled

Squamous NSCLC

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

120 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07157956 2025-09-05

CVL006-T1002

318 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07109531 2025-08-07

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

286 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06970782 2025-05-21

KYLIN-3

278 enrolled

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06963502 2025-05-09

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

762 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06672068 2024-12-30

A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

60 enrolled

Phase 1/2 Not yet recruiting

NSCLC

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

380 enrolled

Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06594874 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Phase 1 Not yet recruiting

350 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06514027 2024-07-23

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

30 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

401 enrolled

Phase 2/3 Not yet recruiting

Non-squamous Non-small Cell Lung Cancer

NCT06211023 2024-01-18

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

520 enrolled

Gynecologic

Ovarian Neoplasms

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

642 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05794659 2023-07-20

Cornerstone4

98 enrolled

Gynecologic

Advanced Ovarian Cancer

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

368 enrolled

Recurrence

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)